Australian adults living with Attention Deficit Hyperactivity Disorder (ADHD) will soon have more affordable access to a life-changing treatment option, thanks to its expanded listing on the Pharmaceutical Benefits Scheme (PBS).
\nOn 1 February, the Government is expanding the listing of Vyvanse\u00ae (lisdexamfetamine) to include patients who are diagnosed with ADHD after they turn 18 years old.
\nThe PBS listing extension means Vyvanse\u00ae is now subsidised for Australians diagnosed as adults, rather than as children.
\nAround 20,000 patients accessed a comparable treatment for this condition and could benefit from this new treatment option. Without PBS subsidy, patients might pay more than $1,200 per year for treatment. They will now pay $41.30 per script, or $6.60 with a concession card.
\nADHD can look different in adults, with some symptoms overlooked. This medicine may help to increase a patient\u2019s ability to pay attention, stay focused, and stop fidgeting.
\nSome studies suggest that up to three per cent of Australian adults have ADHD.
\nThe Australian Government continues to make important medicines available to Australians at affordable prices.
\nThis listing has been recommended by the independent Pharmaceutical Benefits Advisory Committee.
\nSince 2013, the Australian Government has approved more than 2,550 new or amended listings on the PBS. This represents an average of around 30 listings or amendments per month \u2013 or one each day \u2013 at an overall investment by the Government of $12.4 billion.
\nThe Government\u2019s commitment to ensuring Australians can access affordable medicines, when they need them, remains rock solid.<\/p>\n","protected":false},"excerpt":{"rendered":"
Australian adults living with Attention Deficit Hyperactivity Disorder (ADHD) will soon have more affordable access to a life-changing treatment option, thanks to its expanded listing on the Pharmaceutical Benefits Scheme (PBS). On 1 February, the Government is expanding the listing of Vyvanse\u00ae (lisdexamfetamine) to include patients who are diagnosed with ADHD after they turn 18 … Continue reading “Greater access to life-changing medicine for Australians with ADHD”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-10099","post","type-post","status-publish","format-standard","hentry","category-aussie"],"_links":{"self":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts\/10099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=10099"}],"version-history":[{"count":0,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts\/10099\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=10099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=10099"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=10099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}